You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Illumina Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Illumina Company Info
The company develops, manufactures, and markets next-generation life-science tools and integrated systems to analyze genetic variations and biological functions.
News & Analysis
Illumina's top line is going to be under more pressure in the short term as well as in the medium term.
Illumina is having a bumpy ride, but it's playing the long game.
There's an acquisition-driven crisis brewing, not to mention some headwinds.
A couple of these stocks have lost half of their value, just this year.
Investors didn't like an unfavorable EU court decision.
The genomic-sequencing company's CFO is unexpectedly leaving for another company.
Shares are near a 52-week low, but is that cheap enough?
This gene-sequencing leader looks poised to benefit from a pair of long-term trends.
The sky is the limit for the leader in DNA sequencing.
The Fools reveal three stock ideas for investors interested in personalized medicine and precision oncology.
We’re pitting off gene sequencing giant Illumina against giant biotech Gilead Sciences to see which company is the better buy for long-term investors.
A system that could revolutionize gene research and a first-in-class cancer therapy could be two of healthcare's biggest advances this year. Plus, UnitedHealth's earnings review, and a preview of Johnson & Johnson's earnings.
ILMN earnings call for the period ending September 30, 2021.
ILMN earnings call for the period ending June 30, 2021.
ILMN earnings call for the period ending March 31, 2021.
ILMN earnings call for the period ending January 3, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.